食品与发酵工业 >

2025 , Vol. 51 >Issue 24: 18 - 26

DOI: https://doi.org/10.13995/j.cnki.11-1802/ts.042825

研究报告

水苏糖和谷氨酰胺复配的微生态制剂缓解肠易激综合征的临床研究

  • 窦文轩 ,
  • 张程程 ,
  • 于雷雷 ,
  • 田丰伟 ,
  • 薛育政 ,
  • 翟齐啸
展开
  • 1(江南大学 食品学院,江苏 无锡,214222)
    2(江南大学附属医院,江苏 无锡,214222)
第一作者:硕士研究生(薛育政主任医师和翟齐啸教授为共同通信作者,E-mail:yuzhengxue_ahjnu@126.com;zhaiqixiao@jiangnan.edu.cn)

收稿日期: 2025-03-24

  修回日期: 2025-05-02

  网络出版日期: 2026-01-12

基金资助

国家自然科学基金杰出青年科学基金项目(32425044)

收起

Clinical study on efficacy of a microecological preparation combining stachyose and glutamine in alleviating irritable bowel syndrome

  • DOU Wenxuan ,
  • ZHANG Chengcheng ,
  • YU Leilei ,
  • TIAN Fengwei ,
  • XUE Yuzheng ,
  • ZHAI Qixiao
Expand
  • 1(School of Food Science and Technology, Jiangnan University, Wuxi 214122, China)
    2(Affiliated Hospital of Jiangnan University, Wuxi 214222, China)

Received date: 2025-03-24

  Revised date: 2025-05-02

  Online published: 2026-01-12

Fold

摘要

肠易激综合征是一种以腹痛、腹胀伴排便异常为特征的慢性肠道疾病,其发生与肠道菌群失调有关。研究表明水苏糖可以调节肠道菌群,促进有益菌生长;谷氨酰胺有助于修复肠黏膜屏障。基于此,该研究旨在通过随机双盲安慰剂对照实验评估水苏糖和谷氨酰胺复配的微生态制剂对肠易激综合征的改善及其在调节患者肠道菌群方面的作用。该研究在无锡市江南大学附属医院招募60名肠易激综合征患者,进行为期4周的微生态制剂干预,并用市售有治疗肠易激综合征作用的益生菌制剂作为阳性对照。干预后采集粪便样本进行宏基因组测序以分析肠道菌群差异。同时每周评估肠易激综合征严重程度和生活质量量表。结果显示,微生态制剂干预4周后患者的疾病严重程度显著改善,并且相较于益生菌制剂疗效更加温和。其次,患者的肠道菌群整体结构呈现出显著差异。在种水平上,微生态制剂通过上调普通拟杆菌、卵形拟杆菌、粪球菌属物种、诺迪氏拟杆菌、经黏液真杆菌属物种、瘤胃球菌属物种的丰度,从而改善IBS患者的症状。研究结果为后期应用基于益生元的微生态制剂缓解肠易激综合征的相关研究提供了理论基础。

关键词： 肠易激综合征; 肠道菌群; 微生态制剂; 水苏糖; 谷氨酰胺

本文引用格式

窦文轩 , 张程程 , 于雷雷 , 田丰伟 , 薛育政 , 翟齐啸 . 水苏糖和谷氨酰胺复配的微生态制剂缓解肠易激综合征的临床研究[J]. 食品与发酵工业, 2025 , 51(24) : 18 -26 . DOI: 10.13995/j.cnki.11-1802/ts.042825

Abstract

Irritable bowel syndrome (IBS) is a chronic intestinal disorder characterized by abdominal pain, bloating, and abnormal bowel movements, and its occurrence is associated with gut microbiota dysbiosis.Studies have shown that stachyose can regulate the gut microbiota and promote the growth of beneficial bacteria, while glutamine helps to repair the intestinal mucosal barrier.Based on this, the present study aims to evaluate the efficacy of a synbiotic formulation combining stachyose and glutamine in improving IBS symptoms and modulating gut microbiota through a randomized, double-blind, placebo-controlled trial.A total of 60 IBS patients were recruited from the Affiliated Hospital of Jiangnan University in Wuxi for a four-week intervention with the synbiotic formulation.A commercially available probiotic product with known therapeutic effects on IBS was used as a positive control.Fecal samples were collected post-intervention for metagenomic sequencing to analyze differences in gut microbiota.Additionally, IBS severity and quality of life scales were assessed weekly.The results showed that after four weeks of intervention, disease severity in the synbiotic group was significantly improved, with a milder therapeutic effect compared to the probiotic control.Furthermore, the overall structure of the gut microbiota in patients exhibited significant changes.At the species level, the synbiotic formulation alleviated IBS symptoms by increasing the abundance of Bacteroides uniformis, Bacteroides ovatus, Faecalibacterium species, Bacteroides nordii, Akkermansia species, and Ruminococcus species.These findings provide a theoretical basis for the future application of prebiotic-based synbiotic formulations in relieving irritable bowel syndrome.

Key words： irritable bowel syndrome; gut microbiota; microecological preparation; stachyose; glutamine

参考文献

[1] BENJAK HORVAT I, GOBIN I, KRESOVIĆ A, et al.How can probiotic improve irritable bowel syndrome symptoms?[J].World Journal of Gastrointestinal Surgery, 2021, 13(9):923-940.
[2] FORD A C, SPERBER A D, CORSETTI M, et al.Irritable bowel syndrome[J].The Lancet, 2020, 396(10263):1675-1688.
[3] 朱佳杰, 刘珊, 赵鹏程, 等.肠易激综合征的流行病学研究进展[J].国际消化病杂志, 2017, 37(5):271-273.
ZHU J J, LIU S, ZHAO P C, et al.Progress in epidemiological research of irritable bowel syndrome[J].International Journal of Digestive Diseases, 2017, 37(5):271-273.
[4] MORGAN V, PICKENS D, GAUTAM S, et al.Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome[J].Gut, 2005, 54(5):601-607.
[5] WRIGHT-HUGHES A, OW P L, ALDERSON S L, et al.Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype:Post hoc analyses from the ATLANTIS trial[J].Gut, 2025, 74(5):728-739.
[6] VIRAMONTES B E, CAMILLERI M, MCKINZIE S, et al.Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome[J].The American Journal of Gastroenterology, 2001, 96(9):2671-2676.
[7] OLDEN K W, CHEY W D, SHRINGARPURE R, et al.Alosetron versus traditional pharmacotherapy in clinical practice:Effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome[J].Current Medical Research and Opinion, 2019, 35(3):461-472.
[8] GORARD D A, LIBBY G W, FARTHING M J.Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome[J].Alimentary Pharmacology & Therapeutics, 1994, 8(2):159-166.
[9] CONSTANTE M, DE PALMA G, LU J, et al.Saccharomyces boulardii CNCM I-745 modulates the microbiota-gut-brain axis in a humanized mouse model of Irritable Bowel Syndrome[J].Neurogastroenterology and Motility, 2021, 33(3):e13985.
[10] LOPES C M, DE JESUS MONTEIRO C S, DUARTE A P, et al.Probiotics and prebiotics for the treatment of irritable bowel syndrome-a narrative review[J].Journal of Clinical Medicine, 2024, 13(21):6337.
[11] ZOLL B, AHUJA N K.Nutritional therapies for irritable bowel syndrome:A focus on prebiotics and probiotics[J].Current Treatment Options in Gastroenterology, 2020, 18(4):729-739.
[12] KIM J, CHO K, KIM J S, et al.Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial[J].Food Science and Biotechnology, 2020, 29(6):837-844.
[13] GĄSIOROWSKA A, ROMANOWSKI M, WALECKA-KAPICA E, et al.Effects of microencapsulated sodium butyrate, probiotics and short chain fructooligosaccharides in patients with irritable bowel syndrome:A study protocol of a randomized double-blind placebo-controlled trial[J].Journal of Clinical Medicine, 2022, 11(21):6587.
[14] MESSAOUDI M, VIOLLE N, BISSON J F, et al.Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers[J].Gut Microbes,2011, 2(4):256-261.
[15] KESAVELU D SR.The efficacy and safety of combined Senna and probiotic-based bowel preparation for colonoscopy in children[J].Cureus, 2020, 12(9):e10180.
[16] ZHAO Z L, LIU W, PI X E.In vitro effects of stachyose on the human gut microbiota[J].Starch-Stärke, 2021, 73(7-8):2100029.
[17] ZHOU Q Q, VERNE M L, FIELDS J Z, et al.Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome[J].Gut, 2019, 68(6):996-1002.
[18] BAUD A, KENNEDY S P.Targeted metagenomic databases provide improved analysis of microbiota samples[J].Microorganisms, 2024, 12(1):135.
[19] ADEKOYA A E, KARGBO H A, IBBERSON C B.Defining microbial community functions in chronic human infection with metatranscriptomics[J].mSystems,2023,8(6).
[20] MANZOOR M, LESKELÄ J, PIETIÄINEN M, et al.Multikingdom oral microbiome interactions in early-onset cryptogenic ischemic stroke[J].ISME Communications, 2024, 4(1):ycae088.
[21] TIAN P J, CHEN Y, ZHU H Y, et al.Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism:A randomized clinical trial[J].Brain, Behavior, and Immunity, 2022, 100:233-241.
[22] ZHAI L X, HUANG C H, NING Z W, et al.Ruminococcus gnavus plays a pathogenic role in diarrhea-predominant irritable bowel syndrome by increasing serotonin biosynthesis[J].Cell Host & Microbe, 2023, 31(1):33-44.e5.
[23] KIM H J, CAMILLERI M, MCKINZIE S, et al.A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome[J].Alimentary Pharmacology & Therapeutics, 2003, 17(7):895-904.
[24] SUN Y Y, LI M, LI Y Y, et al.The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome:A randomized, double-blind, placebo-controlled trial[J].Scientific Reports, 2018, 8:2964.
[25] 卞立群, 陆芳, 李振华, 等.IBS-SSS、AR及IBS-QOL在IBS临床疗效评价中的反应度分析[J].中国中西医结合杂志, 2016, 36(10):1191-1196.
BIAN L Q, LU F, LI Z H, et al.Analysis of response of IBS-SSS, AR, and IBS-QOL in IBS clinical effect evaluation[J].Chinese Journal of Integrated Traditional and Western Medicine, 2016, 36(10):1191-1196.
[26] PITTAYANON R, LAU J T, YUAN Y H, et al.Gut microbiota in patients with irritable bowel syndrome:A systematic review[J].Gastroenterology, 2019, 157(1):97-108.
[27] HIIPPALA K, KAINULAINEN V, SUUTARINEN M, et al.Isolation of anti-inflammatory and epithelium reinforcing Bacteroides and Parabacteroides spp.from a healthy fecal donor[J].Nutrients, 2020, 12(4):935.
[28] DUAN R Q, ZHU S W, WANG B, et al.Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing:A systematic review[J].Clinical and Translational Gastroenterology, 2019, 10(2):e00012.
[29] 刘文续, 王嘉良, 李嘉臻, 等.鼠李糖乳酪杆菌CCFM1069缓解便秘及其对便秘患者肠道菌群影响的临床研究[J].食品与发酵工业,2025,51(19):1-8.
LIU W X, WANG J L, LI J Z, et al.A clinical study on effect of Lactobacillus rhamnosus CCFM1069 in alleviating constipation and its influence on gut microbiota of constipated patients[J].Food and Fermentation Industries,2025,51(19):1-8.
Options
文章导航

/

〈 〉

技术支持：北京玛格泰克科技发展有限公司